Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 37Radiotherapy 31Oxaliplatin 29Cisplatin 28Paclitaxel 24Leucovorin 22Irinotecan 19Docetaxel 13pembrolizumab 10Capecitabine 10Carboplatin 9Radiation 8Neoadjuvant Therapy 8Cetuximab 8Surgical Procedures, Operative 7Folfox protocol 7Chemotherapy, Adjuvant 6Nivolumab 5Gefitinib 5Taxes 4Erlotinib Hydrochloride 4Biopsy 4durvalumab 3Panitumumab 3Itraconazole 3Epirubicin 3Bevacizumab 3tremelimumab 2spartalizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma Of Esophagus × obeticholic acid × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡